Loading
Life sciences · Journal article
Virology Journal · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Cervical cancer, a significant global health challenge, is strongly associated with persistent infection with high-risk human papillomavirus (HPV), particularly HPV-16. The viral oncoproteins E5 and E6 are critical to HPV-mediated carcinogenesis, as they promote cell proliferation, immune evasion, apoptosis resistance, and genomic instability. E5 contributes to tumor progression by modulating growth factor signaling and promoting cell survival. E6, on the other hand, primarily drives malignant transformation by targeting the tumor suppressor p53 for degradation. Given their pivotal roles in cervical cancer, both oncoproteins are promising therapeutic targets. Recent advancements in gene-silencing technologies have provided novel opportunities for the selective inhibition of HPV oncogenes. Small interfering RNAs (siRNAs) and CRISPR/Cas-based genome-editing systems have demonstrated significant potential in suppressing E5 and E6 expression, restoring tumor suppressor functions, inducing apoptosis, and enhancing the sensitivity of cancer cells to conventional therapies. This narrative review summarizes the biological functions of HPV16-derived E5 and E6 in cervical carcinogenesis, and discusses recent developments in gene-silencing strategies targeting these oncogenes. Furthermore, it highlights current challenges, therapeutic limitations, and future perspectives for developing targeted molecular approaches aimed at cervical cancer prevention and treatment.